Effective control of catatonia in Parkinson's disease by electroconvulsive therapy: a case report.
Kamigaichi
R
R
Kubo
S
S
Ishikawa
K
K
Yokoyama
K
K
Ogaki
K
K
Usui
C
C
Hatta
K
K
Arai
H
H
Mochizuki
H
H
Hattori
N
N
D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage; D001381:Azepines / Q000008:administration & dosage; D052160:Benzothiazoles / Q000008:administration & dosage; D000077465:Cabergoline; D002230:Carbidopa / Q000008:administration & dosage; D002389:Catatonia / Q000209:etiology / Q000628:therapy*; D002396:Catechols / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D004565:Electroconvulsive Therapy; D004873:Ergolines / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage; D009570:Nitriles / Q000008:administration & dosage; D010300:Parkinson Disease / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D000077487:Pramipexole
D000978:Antiparkinson Agents; D001381:Azepines; D052160:Benzothiazoles; D002396:Catechols; D004873:Ergolines; D009570:Nitriles; D007980:Levodopa; C071192:entacapone; C024763:talipexole; D000077487:Pramipexole; D000077465:Cabergoline; D002230:Carbidopa